跳至主要内容
临床试验/NCT01691300
NCT01691300已完成不适用

C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment

Chang Gung Memorial Hospital2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2011年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
2
主要终点
Pretreatment lesion detection

研究概览

简要总结

Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • at least 20 years of age
  • previously untreated
  • complete pre-treatment clinical staging including bone marrow examination
  • written informed consent to participate in the study

排除标准

  • concurrent active malignant tumor(s)
  • pregnant or breast feeding women
  • non-compliant to PET/CT or to MRI
  • marked renal impairment (contraindicated for contrast-enhanced MRI)

结局指标

主要结局

Pretreatment lesion detection

时间窗: Within 2 weeks before initiation of therapy

Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI

次要结局

  • Post-ASCT response assessment(Approximately 3 months after ASCT)
  • Post-induction response assessment(Approximately 4 months after initiation of therapy depending on the regimen)

研究者

发起方
Chang Gung Memorial Hospital
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验